Promarker®D and Promarker®Eso hit the market in WA and NT
As of 14 September 2026, Proteomics International Laboratories Ltd (ASX: PIQ) has commenced the controlled market release of Promarker®D and Promarker®Eso in Western Australia and the Northern Territory. The rollout activates the exclusive Australian pathology distribution agreement with Healius Limited (ASX: HLS) that was first announced on 22 July 2026.
The Healius distribution deal, signed in July 2026, established the exclusive three-year partnership that now underpins this controlled release, giving the Promarker® portfolio immediate access to Healius’ established referrer relationships with GPs, specialists, and hospitals across Australia.
The controlled release phase is designed to support operational and systems readiness ahead of a broader national rollout. Subject to the successful completion of implementation activities, broader commercial sales are expected to follow in Q2 FY27. Healius brings a nationwide network of approximately 1,900 collection centres to the agreement, making it the first national commercial distribution partnership secured for the Promarker® portfolio.
When big ASX news breaks, our subscribers know first
Understanding the Promarker® tests and what they detect
What is proteomics?
Proteomics is the industrial-scale study of the structure and function of proteins. Because proteins can reflect biological changes in the body before symptoms emerge, they serve as indicators for early disease detection.
The Promarker® test portfolio
Two tests are now live in WA and NT, with a third advancing through development. The table below summarises the current portfolio.
| Test | Condition Targeted | Clinical Use | Patient Price | Status |
|---|---|---|---|---|
| Promarker®D | Diabetic kidney disease | Risk assessment up to four years before clinical symptoms appear | $495 | Live — WA & NT |
| Promarker®Eso | Oesophageal cancer | Assists in ruling out cancer in patients with chronic reflux | $997 | Live — WA & NT |
| Promarker®Endo | Endometriosis | Assists in the diagnosis of endometriosis | Not yet set | Assay refinement and validation in progress |
Both live tests are currently available on a private-pay basis only. Reimbursement strategies are being progressed separately by the company.
How the commercial model works
The operating model divides responsibilities between the two parties:
- Proteomics International: laboratory testing, clinical reporting, scientific support, and quality and regulatory compliance
- Healius: specimen collection, pathology distribution, and commercial delivery to primary care and specialist referrers
The controlled WA and NT release serves a specific operational purpose — testing systems and readiness before scaling nationally. Once implementation activities are successfully completed, national rollout is expected to commence in Q2 FY27.
David Morris, CEO and Managing Director, Proteomics International
“We have made good progress since signing our national distribution agreement with Healius. Promarker®D and Promarker®Eso are ready for a controlled market release, with broader national commercial launch expected to commence during Q2 FY27.”
Morris also noted that alongside the Healius rollout, the company continues to progress reimbursement strategies and advance Promarker®Endo assay refinement and validation, describing these as “important to the broader commercial development of the Promarker portfolio…” with a focus on “…disciplined execution as we progress the commercialisation of the portfolio.”
What this means for investors
The announcement marks a tangible step from agreement-signing to actual patient access. Several strategic points are worth noting:
- First national commercial distribution partnership: The company confirms this is the first national commercial distribution partnership secured for the Promarker® portfolio, a milestone in the product’s commercialisation history.
- Capital-efficient distribution: Access to Healius’ approximately 1,900 collection centres removes the need for Proteomics International to build its own national specimen collection network, representing a meaningful operational efficiency.
- Pricing now public: With Promarker®D set at $495 and Promarker®Eso at $997, the market has publicly disclosed pricing from which adoption scenarios can begin to be modelled independently.
- Three-product pipeline depth: Two tests are now live, while Promarker®Endo continues through assay refinement and validation, with achievement of the next clinical milestone subject to successful completion of the validation programme.
- Reimbursement pathway in progress: Reimbursement strategies are under active development, representing a potential future catalyst if reimbursement is achieved.
It is important to note that, as the Promarker® portfolio is at an early stage of commercialisation, the company has explicitly stated that revenue generated under the distribution agreement cannot be reliably estimated at this time. Investors should frame this development in terms of strategic positioning rather than near-term financial returns.
Don’t Miss the Next Healthcare Breakthrough on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.